Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

9.680 +0.130 (+1.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,010,323
Open 9.500
Bid (Size) 9.650 (3,200)
Ask (Size) 10.05 (10,000)
Prev. Close 9.550
Today's Range 9.480 - 9.755
52wk Range 6.000 - 11.22
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen ↗
Via Chartmill
News headline image
BioCryst (BCRX) Q2 2026 Earnings Call Transcript ↗
ORLADEYO revenue hit $158.2M with 10% growth as pediatric launch exceeded expectations. 
Via The Motley Fool
Topics Earnings

Performance

YTD
+29.1%
+29.1%
1 Month
+3.6%
+3.6%
3 Month
+14.3%
+14.3%
6 Month
+27.7%
+27.7%
1 Year
+15.4%
+15.4%

More News

Read More
News headline image
BioCryst Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
BioCryst Pharmaceuticals (NASDAQ:BCRX) Surges on Q2 Earnings Beat ↗
Via Chartmill
News headline image
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
From BioCryst Pharmaceuticals, Inc.
Via GlobeNewswire
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Q1 2026 Results: Revenue Beat, EPS Miss ↗
Via Chartmill
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Shatters Q4 2025 Estimates with Stellar Earnings Beat ↗
Via Chartmill
News headline image
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
From BioCryst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances ↗
Via MarketBeat
News headline image
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings ↗
Via Benzinga
News headline image
BioCryst (BCRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play ↗
Via Stocktwits
BioCryst To Acquire Astria Therapeutics In $700M Deal ↗
Via Stocktwits
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
BioCryst (BCRX) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue ↗
Via Chartmill
Topics Earnings
News headline image
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' ↗
Via Benzinga

Frequently Asked Questions

Is BioCryst Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, BioCryst Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does BioCryst Pharmaceuticals, Inc. - Common Stock trade on?
BioCryst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock is BCRX on the Nasdaq Stock Market
What is the current price of BioCryst Pharmaceuticals, Inc. - Common Stock?
The current price of BioCryst Pharmaceuticals, Inc. - Common Stock is 9.680
When was BioCryst Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of BioCryst Pharmaceuticals, Inc. - Common Stock was at 08/24/26 04:00 PM ET
What is the market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock?
The market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock is 1.80B
How many shares of BioCryst Pharmaceuticals, Inc. - Common Stock are outstanding?
BioCryst Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.